consider
advanc
made
forens
analysi
microb
toxin
advanc
includ
sequenc
genom
microscopi
underdevelop
underutil
area
microbi
forens
host
interact
microorgan
way
provid
uniqu
signatur
forens
use
forens
purpos
immedi
goal
distinguish
potenti
victim
innoc
person
perpetr
distinguish
natur
acquir
intent
infect
two
princip
method
suffici
develop
character
humor
immun
respons
identif
vaccineinduc
immun
antibiot
may
present
possibl
perpetr
chapter
present
central
element
host
respons
simplifi
fashion
describ
repres
exampl
appropri
context
high
potenti
provid
evid
may
aid
investig
distinguish
perpetr
victim
expos
particular
microb
byproduct
toxin
chapter
also
present
nonmicrobi
forensicedirect
inform
immun
system
interest
reader
fuller
understand
immun
respons
gener
primari
aim
microbi
forens
identifi
biolog
agent
sourc
individu
respons
event
budowl
et
al
analyt
approach
differ
suspect
biothreat
agent
encount
contain
environ
oppos
vivo
human
anim
plant
analys
trace
element
pollen
growth
media
latent
fingerprint
microbi
nonmicrobi
nucleic
acid
applic
contain
environment
sampl
state
et
al
howev
microorgan
toxin
live
host
longer
possibl
analyz
preced
item
except
microbi
nucleic
acid
howev
host
respons
biolog
agent
may
avail
analysi
clue
akin
forens
studi
physic
trace
bite
mark
scratch
wound
trajectori
size
wound
often
surrog
evid
teeth
fingernail
bullet
averil
odontolog
forens
pathologist
familiar
evid
relat
determin
manner
death
includ
host
respons
involv
healthcar
alon
familiar
host
respons
context
microbi
forens
import
integr
intellig
inform
may
includ
analyt
data
attribut
pictur
physician
healthcar
provid
may
among
first
realiz
patient
victim
biocrim
case
covert
attack
may
physician
medic
examin
first
recogn
index
case
healthcar
worker
key
posit
preserv
critic
evid
therebi
contribut
investig
schutzer
et
al
number
step
follow
possibl
biolog
attack
aris
either
consent
patient
individu
compel
law
interact
public
health
law
enforc
joint
statement
fbi
cdc
dh
advis
call
fbi
public
health
author
suspici
situat
aris
investig
et
al
guidelin
procedur
report
suspicion
biocrim
provid
center
diseas
control
prevent
cdc
http
wwwcdcgov
feder
bureau
investig
fbi
http
wwwfbigov
depart
homeland
secur
dh
http
wwwdh
gov
detail
previou
articl
schutzer
et
al
host
respons
microorgan
foreign
substanc
often
wellorchestr
seri
event
may
protect
individu
harm
zabriski
time
host
respons
may
provid
clue
ident
offend
microorgan
toxin
well
rough
chronolog
occur
long
persist
emerg
technolog
transcript
array
bioinformat
analysi
eventu
refin
method
valid
provid
even
greater
help
delin
pathway
compon
host
respons
infecti
agent
sala
et
al
popper
et
al
ko
et
al
technolog
suffici
matur
use
today
immun
system
compon
mainstay
protect
infect
malign
zabriski
paul
murphi
weaver
inflamm
often
side
effect
immun
system
contain
erad
microorgan
elimin
foreign
tissu
specif
arm
immun
system
use
marker
support
presenc
infect
humor
antibodi
respons
invad
microorgan
one
exampl
specif
arm
forens
valu
antibodi
produc
may
protect
role
togeth
part
immun
system
erad
pathogen
neutral
toxin
antibodi
may
effect
role
howev
abil
recogn
uniqu
specif
microbi
antigen
serv
indic
specif
microorgan
recent
present
present
past
case
vaccin
specif
antibodi
may
recogn
highli
specif
epitop
one
microb
versu
relat
microb
eg
influenza
viru
especi
differ
recombin
vaccin
could
forens
import
substanc
antibiot
rapidli
kill
pathogen
may
modifi
immun
respons
remov
reduc
infecti
drive
forc
fullscal
respons
note
clinic
veterinari
medicin
measur
immun
respons
help
diagnostician
decid
infect
present
recent
situat
intent
provid
treatment
forens
scientist
may
exploit
part
immun
respons
discov
like
victim
attack
might
respons
chapter
discuss
basic
host
immun
respons
simplifi
manner
util
forens
sens
exampl
provid
sens
inform
achiev
use
host
factor
microbi
forens
like
provid
clue
high
degre
certainti
respons
new
exposur
microb
innat
immun
system
may
first
line
defens
immun
system
start
activ
antibodi
system
typic
cell
known
macrophag
ingest
degrad
invad
pathogen
present
part
antigen
microorgan
helper
cell
lymphocyt
direct
lymphocyt
known
b
cell
produc
antibodi
antigen
particular
microb
present
usual
take
least
day
microbespecif
antibodi
detect
parslow
antibodi
specif
form
protein
known
immunoglobulin
ig
igm
igg
iga
secretori
iga
princip
class
immunoglobulin
prime
relev
chapter
discuss
detail
infect
immunoglobulin
usual
appear
order
igm
igg
iga
b
cell
first
begin
produc
igm
b
cell
undergo
irrevers
switch
produc
igg
later
b
cell
undergo
switch
becom
igasecret
b
cell
immunoglobulin
persist
vari
time
exampl
halflif
particular
igm
antibodi
approxim
day
igg
long
day
tabl
paul
murphi
weaver
certain
circumst
rule
rule
suspect
specif
ige
may
valu
individu
unfortun
allergi
problem
due
ige
allergen
ragwe
peanut
cat
dander
case
ige
molecul
sit
surfac
mast
cell
basophil
cell
releas
histamin
allerg
mediat
offend
allergen
bridg
two
ige
molecul
similar
effect
infect
live
microb
vaccin
often
design
provok
antibodi
respons
vaccin
compos
live
attenu
microb
whole
nonprolifer
microb
antigen
recombin
part
microb
toxoid
regardless
intent
immun
vaccin
engend
protect
often
gener
protect
neutral
antibodi
although
halflif
individu
igg
molecul
less
month
popul
antibodi
igg
isotyp
form
may
persist
life
memori
b
cell
sustain
antibodi
retain
abil
quickli
gener
appropri
antibodi
challeng
immun
system
encount
anoth
infect
subject
revaccin
booster
result
acceler
product
particular
antibodi
increas
level
antibodi
circul
blood
fig
perhap
pattern
antibodi
respons
forens
valu
provid
timefram
appear
igm
first
follow
bcell
switch
longerlast
igg
earli
phase
exposur
igm
predomin
time
goe
igg
may
wax
wane
igm
longer
found
fig
antibodi
respons
particular
agent
may
direct
differ
antigen
differ
time
earli
later
initi
exposur
respons
often
involv
igm
earli
stage
igg
later
late
cours
bennett
et
al
viru
known
caus
mononucleosi
acut
earli
diseas
common
find
high
level
antibodi
igm
isotyp
viral
earli
antigen
ea
viral
capsid
antigen
vca
rare
find
igg
antibodi
vca
epsteinebarr
nuclear
acid
ebna
anyth
low
titer
level
patient
recov
first
infect
ebv
rare
find
anyth
low
level
igm
ea
vca
igg
vca
higher
increas
level
common
antibodi
ebna
often
low
stage
sever
month
clinic
recoveri
igm
ea
vca
remain
low
level
wherea
igg
vca
ebna
present
high
level
often
year
control
experi
normal
clinic
event
illustr
happen
immun
system
respond
infecti
agent
vaccin
control
experi
may
laboratori
anim
patient
illustr
concept
receiv
booster
vaccin
uncontrol
normal
clinic
event
occur
patient
reexpos
infecti
agent
consid
gener
antigen
exposur
first
time
immun
system
encount
antigen
x
agx
respond
shown
fig
initi
antibodi
agx
bare
discern
level
rise
later
fall
plateau
simultan
exposur
occur
agx
new
agi
anoth
microorgan
immun
system
would
quickli
mount
brisk
respons
high
level
ab
agx
cours
ab
agi
would
slow
delay
respons
first
exposur
agx
phenomenon
term
immunolog
memori
amnest
respons
use
symptom
sign
exposur
either
x
similar
case
earli
flulik
symptom
pulmonari
anthrax
raymond
et
al
water
robertson
bush
et
al
influenza
viru
meltzer
et
al
cao
et
al
lessler
et
al
anoth
exampl
common
us
repetit
exposur
differ
strain
flu
virus
meltzer
et
al
janeway
illustr
tabl
person
infect
first
time
one
strain
influenza
viru
respons
antigen
theoret
exampl
ag
three
year
later
individu
expos
partial
similar
influenza
viru
respond
preferenti
antigen
also
present
origin
influenza
viru
person
also
make
smaller
initi
antibodi
respons
new
antigen
share
first
viru
ten
year
later
new
flu
season
exposur
third
strain
influenza
brisk
respons
would
antigen
previous
recogn
immun
system
scientif
basi
give
flu
vaccin
contain
varieti
possibl
antigen
common
multipl
strain
flu
viru
rapid
protect
antibodi
respons
occur
util
serolog
analysi
peopl
expos
anthrax
strength
limit
knowledg
humor
respons
infect
biothreat
microb
limit
compar
knowledg
kinet
respons
common
human
infect
nevertheless
appropri
context
suffici
background
inform
detect
antibodi
particular
microb
antigen
import
valu
microbi
forens
investig
inform
may
critic
prob
valu
guid
investig
lead
absenc
specif
antibodi
respons
may
also
valu
particular
investig
certainli
import
increas
context
inform
organ
could
involv
exposur
like
occur
rout
exposur
symptom
sign
manifest
host
data
presenc
antigen
microbi
nucleic
acid
jackson
et
al
inform
mani
host
peopl
anim
infect
geograph
region
incid
background
preval
antibodi
titer
organ
question
relat
organ
popul
studi
also
import
vaccin
respons
forens
valu
current
protect
antigen
pa
vaccin
small
amount
ef
lethal
factor
lf
respons
side
effect
one
might
expect
see
antibodi
antigen
well
pa
recombin
pa
pa
antilf
antief
would
absent
immun
individu
anthraxlett
attack
rais
multipl
question
everi
person
infect
possibl
expos
vaccin
treat
question
includ
person
infect
spore
break
skin
cutan
anthrax
inhal
spore
pulmonari
anthrax
bennett
et
al
ingest
gastrointestin
anthrax
bravata
et
al
tutron
et
al
among
worri
well
consid
situat
close
associ
come
symptom
compat
inhal
anthrax
receiv
letter
contain
powder
materi
longer
avail
shown
anthrax
great
worri
ensu
sever
case
document
exposur
enough
time
patient
develop
antibodi
specif
anthrax
antigen
least
probe
igg
serial
serum
sampl
obtain
novemb
test
igg
antibodi
pa
compon
anthrax
toxin
enzymelink
immunosorb
assay
elisa
sampl
nonreact
serial
test
serum
igg
antibodi
pa
toxin
anthrax
perform
workplaceexpos
person
one
test
neg
specimen
collect
octob
traeger
et
al
instruct
look
posit
antibodi
case
context
natur
util
serolog
analysi
peopl
expos
anthrax
strength
limit
durat
individu
symptom
develop
posit
test
ernesto
blanco
mailroom
clerk
case
experienc
fatigu
septemb
work
mailroom
ami
build
deliv
mail
index
case
septemb
develop
nonproduct
cough
intermitt
fever
runni
nose
conjunct
sign
worsen
octob
hospit
addit
short
breath
exert
sweat
mild
abdomin
pain
vomit
episod
confus
temperatur
elev
c
f
heart
rate
rapid
respiratori
rate
slightli
fast
blood
pressur
mm
hg
bilater
conjunctiv
inject
bilater
pulmonari
rhonchi
time
admiss
neurolog
exam
normal
skin
lesion
observ
laboratori
abnorm
low
albumin
elev
liver
transaminas
borderlin
low
serum
sodium
increas
creatinin
low
oxygen
content
blood
blood
cultur
neg
hospit
day
antibiot
start
chest
xray
show
leftsid
pneumonia
small
left
pleural
effus
classic
mediastin
widen
dewan
et
al
patient
initi
given
intraven
azithromycin
cefotaxim
ciprofloxacin
subsequ
ad
nasal
swab
obtain
octob
grew
bacillu
anthraci
cultur
comput
tomographi
ct
chest
show
bilater
effus
multilobar
pulmonari
consolid
still
signific
mediastin
lymphadenopathi
pleural
fluid
aspir
posit
b
anthraci
dna
pcr
bacteri
cultur
bronchial
wash
pleural
fluid
neg
immunohistochem
stain
transbronchi
biopsi
demonstr
presenc
b
anthraci
capsul
cell
wall
antigen
hospit
white
blood
count
rose
fluid
second
thoracentesi
posit
b
anthraci
dna
pcr
immunohistochem
stain
pleural
fluid
cell
pleural
biopsi
tissu
demonstr
presenc
b
anthraci
capsul
cell
wall
antigen
serial
serum
sampl
demonstr
fourfold
rise
serum
igg
antibodi
pa
compon
anthrax
toxin
elisa
assay
patient
abl
leav
hospit
octob
oral
ciprofloxacin
tabl
illustr
clinic
microbi
forens
approach
context
analyz
patient
like
common
situat
biocrim
question
includ
infect
acquir
natur
intent
action
led
infect
particular
individu
acquir
natur
infectiondwa
target
bystand
altern
possibl
right
circumst
laboratoryacquir
infect
case
also
demonstr
cultur
may
neg
differ
time
differ
fluid
tissu
earli
administr
antibiot
howev
remnant
infect
even
dead
organ
found
probe
antigen
dna
patient
respons
demonstr
classic
principl
infecti
diseas
rise
antibodi
titer
time
case
igg
particular
antigen
compon
anthrax
toxin
friedland
littl
cunningham
et
al
subject
antibodi
respons
may
detect
earlier
igm
compon
antigen
anthrax
sought
case
also
point
util
integr
presenc
antibodi
indic
anthrax
infect
cultur
pcr
antigen
detect
take
greatest
signific
clinic
ill
someon
possibl
expos
earli
administr
antibiot
prevent
interfer
isol
pathogen
cultur
kaeberlein
et
al
first
pulmonari
anthrax
case
associ
letter
attack
three
patient
isol
b
anthraci
clinic
sampl
howev
cultur
attempt
initi
antibiot
therapi
histori
exposur
conjunct
compat
symptom
sign
diseas
object
laboratori
find
basi
diagnosi
b
anthraci
identifi
pleural
fluid
pleural
biopsi
transbronchi
biopsi
specimen
reactiv
b
anthracisspecif
cell
wall
capsular
antibodi
detect
dna
pleural
fluid
blood
pcr
jernigan
et
al
import
understand
limit
assay
use
medicin
forens
budowl
et
al
schutzer
et
al
iggbas
elisa
antipa
illustr
import
understand
limit
assay
elisa
develop
us
armi
medic
research
institut
infecti
diseas
usamriid
put
oper
optim
intern
valid
cdc
function
sensit
specif
detect
antibodi
respons
b
anthraci
infect
major
limit
one
antigen
use
igg
measur
therefor
neg
result
shortli
exposur
may
effect
falseneg
result
gap
may
fill
develop
assay
antigenspecif
igm
probe
b
anthraci
antigen
epitop
yet
character
assay
may
use
present
form
screen
asymptomat
peopl
possibl
exposur
studi
dewan
et
al
dewan
et
al
provid
contemporari
background
databas
group
postal
worker
may
expos
b
anthraci
begin
octob
postal
employe
other
washington
dc
postal
facil
went
dc
gener
hospit
antibiot
addit
peopl
whose
treatment
began
octob
serum
sampl
also
obtain
individu
washington
dc
postal
facil
preciou
week
neg
specif
antipa
igg
includ
three
individu
report
remot
histori
anthrax
vaccin
consist
neg
find
may
explain
fact
antibiot
therapi
initi
serum
test
baselin
serum
sampl
avail
test
addit
time
period
exposur
sampl
short
among
individu
capitol
region
cultureposit
nasal
swab
receiv
prophylact
antibiot
immedi
none
posit
cultur
nasal
swab
repeat
day
later
none
develop
igg
pa
antigen
day
exposur
emphas
limit
interpret
test
someon
earli
antibiot
treatment
rais
forens
util
consider
even
easili
dissemin
spore
antibodi
respons
may
abort
modifi
antibiot
earli
erad
furthermor
antibiot
taken
exposur
would
like
effect
prevent
laboratori
clinic
sign
infect
detect
microbi
dna
antigen
organ
person
bodi
cloth
possess
rais
red
flag
exposur
rout
infect
import
interpret
result
limit
assay
use
exampl
cutan
anthrax
paraguay
illustr
notion
well
need
search
antigen
marker
exposur
harrison
et
al
analysi
outbreak
case
cutan
anthrax
follow
contact
raw
meat
sick
cow
sera
case
coloni
noncoloni
control
examin
western
blot
antibodi
pa
lf
week
outbreak
elisa
use
probe
antibodi
polydglutam
acid
capsul
case
antibodi
pa
sensit
none
control
posit
case
antibodi
lf
control
neg
anticapsul
antibodi
posit
also
posit
control
result
studi
demonstr
need
consid
antigen
principl
discuss
highlight
report
sever
acut
respiratori
syndrom
sar
appear
alon
coronaviru
respons
diseas
evok
concern
possibl
terrorist
origin
onset
report
morbid
mortal
weekli
report
mmwr
cfdcap
preval
igg
antibodi
sarsassoci
coronaviru
anim
trader
discuss
need
valid
interpret
test
appropri
popul
also
discuss
inabl
date
time
infect
igg
assay
possibl
assay
crossreact
near
neighbor
might
unknown
prome
bulletin
dr
steve
berger
look
data
differ
perspect
report
week
studi
mmwr
indic
anim
contact
may
inde
promot
infect
howev
strike
find
seem
elud
author
percent
percent
individu
healthi
control
group
adult
also
found
seroposit
popul
guangdong
provinc
million
million
adult
age
assum
seroposit
rate
among
control
repres
provinc
whole
adult
guangdong
time
infect
sar
viru
figur
total
number
sar
patient
report
worldwid
date
comparison
good
illustr
advantag
open
dissemin
discuss
inform
well
need
question
methodolog
acquisit
data
accept
applic
formula
analys
forens
epidemiolog
also
valu
rememb
mani
infect
includ
mani
sar
coronaviru
asymptomat
mildli
symptomat
plagu
zoonot
infect
caus
yersinia
pesti
occur
western
unit
state
regular
anim
reservoir
bennett
et
al
situat
natur
occur
yersinia
contrast
appear
case
smallpox
would
rais
immedi
red
flag
bioterrorist
event
case
need
approach
epidemiolog
standpoint
first
determin
whether
natur
acquir
case
whether
fact
point
deliber
introduct
organ
analyt
techniqu
could
includ
genom
analysi
isol
organ
immunolog
respons
host
new
era
rapid
deep
sequenc
capac
investig
genom
grow
mardi
stavnsbjerg
et
al
consider
anim
reservoir
elisa
assay
compar
test
detect
plagu
antibodi
antigen
multimamm
mice
mastomi
coucha
mastomi
natalensi
shepherd
et
al
experiment
infect
sacrif
daili
interv
igg
elisa
equival
sensit
passiv
hemagglutin
sensit
igm
elisa
complement
fixat
antibodi
detect
day
infect
use
four
test
igm
elisa
titer
fell
undetect
level
week
plagu
fraction
antigen
detect
bacterem
sera
coucha
natalensi
antibodi
pattern
comparison
show
principl
igm
versu
igg
pathogen
work
tempor
situat
infect
earli
versu
late
past
event
also
show
inform
combin
antigen
detect
engend
confid
result
note
conclus
older
refer
substanti
defin
antigen
assay
technolog
melioidosi
caus
burkholderia
pseudomallei
ashdown
key
clinic
sign
laboratori
result
may
rais
possibl
infect
pathogen
whether
acut
persist
past
infect
determin
assess
sever
host
respons
often
simpl
indic
erythrocyt
sediment
rate
creactiv
protein
crp
rais
clinic
suspicion
infect
studi
patient
clinic
melioidosi
cultureposit
cultureneg
rel
unev
diseas
cours
initi
elev
serum
crp
decreas
antibiot
therapi
return
normal
diseas
resolv
anoth
seri
patient
igm
igg
measur
elisa
sera
septicem
case
sera
case
local
melioidosi
chenthamarakshan
et
al
sixtyf
sera
cultureneg
case
seroneg
endem
infect
suspect
melioidosi
also
examin
control
includ
serum
nonmelioidosi
case
highexposur
risk
case
healthi
individu
iggelisa
sensit
specif
sera
case
septicem
local
infect
sera
clinic
suspect
melioidosi
case
posit
igg
antibodi
sensit
specif
igm
elisa
respect
geometr
antibodi
index
igm
antibodi
sera
melioidosi
case
significantli
higher
case
compar
noncas
control
anoth
studi
author
rapid
test
igg
igm
shown
clinic
util
cuzzubbo
et
al
studi
intent
evalu
util
igg
assay
compar
assay
illustr
clinic
tempor
context
must
integr
interpret
dharakul
et
al
also
illustr
room
technic
improv
test
best
set
often
endem
area
least
use
sampl
area
infect
occur
test
evalu
actual
clinic
set
area
endem
melioidosi
specif
igg
igm
assay
significantli
better
indirect
hemagglutin
test
iha
sensit
igg
assay
higher
iha
test
igm
test
specif
igg
found
septicem
case
local
infect
igg
test
also
better
igm
test
iha
test
identifi
acut
melioidosi
case
first
day
admiss
igg
antibodi
b
pseudomallei
antigen
remain
high
longer
year
recov
diseasefre
patient
diseas
may
incub
day
year
acut
case
may
well
detect
rise
specif
igm
matter
day
infect
although
endem
southeast
asia
b
pseudomallei
use
biothreat
agent
differ
environ
cours
manifest
may
recogn
due
unfamiliar
diseas
exampl
also
point
context
test
use
determin
valuabl
concept
predict
valu
instruct
determin
use
test
may
term
diseas
detect
high
posit
predict
valu
indic
test
use
determin
diseas
present
high
neg
predict
valu
would
indic
test
use
exclud
presenc
diseas
anoth
zoonot
agent
rift
valley
fever
viru
rvfv
transmit
via
aerosol
clark
et
al
one
studi
intent
look
improv
test
show
util
igm
determin
earli
exposur
rvfv
niklasson
et
al
two
elisa
igm
test
detect
specif
igm
antibodi
rvfv
first
week
vaccin
three
inactiv
vaccin
dose
given
day
elisa
serum
igm
day
neg
lower
rang
detect
day
serum
antibodi
valu
strongli
posit
day
wane
later
collect
sampl
neg
plaqu
reduct
neutral
test
neg
day
becam
posit
later
sampl
similar
exampl
shown
data
suggest
three
dose
rvfv
vaccin
induc
prolong
primari
antibodi
respons
author
studi
conclud
elisa
igm
may
use
earli
diagnosi
acut
human
infect
good
correl
neutral
test
elisa
igg
would
indic
later
infect
taken
togeth
exampl
illustr
ideal
test
analysi
clinic
forens
use
would
incorpor
endem
incid
area
control
histor
contextu
inform
knowledg
rout
exposur
background
incid
kinet
transmiss
scenario
must
take
account
multipl
factor
limit
analyt
process
appli
one
extrem
situat
occur
onset
acquir
immunodefici
syndrom
aid
human
immun
defici
viru
hiv
unit
state
initi
case
therefor
precis
highli
sensit
specif
test
excel
posit
neg
predict
valu
exist
combin
test
use
would
like
yield
posit
result
area
littl
hiv
infect
diseas
onset
kansa
posit
test
today
methodolog
serum
sampl
kansa
would
consid
probabl
falseposit
warrant
investig
today
sever
viral
nucleic
acid
assay
avail
would
provid
definit
diagnosi
short
period
time
bennett
et
al
howev
sampl
test
begin
hiv
test
could
posit
person
adult
tcell
leukemia
caus
human
tcell
leukemia
origin
test
becam
known
aid
involv
whole
viral
lysat
sera
crossreact
question
regard
interpret
test
result
could
rais
knowledg
differ
present
infect
exampl
actual
use
laboratori
immort
cell
patient
actual
increas
tcell
count
natur
leukemia
instead
decreas
hiv
infect
laboratori
indic
hypercalcemia
would
rais
leukemia
consider
interpret
posit
laboratori
test
must
also
take
account
health
statu
person
test
import
practic
medicin
relev
extend
forens
analysi
schutzer
et
al
follow
exampl
illustr
concept
individu
syphili
treponem
bacteri
infect
typic
posit
fluoresc
treponem
antibodi
test
result
year
even
success
treatment
howev
infect
would
posit
vener
diseas
research
laboratori
vdrl
test
revert
neg
follow
success
antibiot
therapi
vdrl
test
detect
nonspecif
anticardiolipid
antibodi
produc
falseposit
result
condit
eg
pregnanc
notabl
except
relat
crossreact
epitop
autoimmun
diseas
readili
distinguish
histori
clinic
inform
similarli
individu
infect
activ
tuberculosi
like
posit
skin
test
mantoux
posit
interferongamma
releas
assay
dewan
et
al
ota
kato
wherea
uninfect
healthi
person
neg
certain
instanc
sick
person
cellmedi
immun
defici
anerg
hesh
neg
multipl
skin
test
includ
common
antigen
candida
key
differ
great
differ
healthi
person
test
ill
immunocompromis
individu
subject
test
test
may
also
discrimin
length
infect
ie
acut
chronic
limit
test
may
lead
differ
interpret
unless
one
familiar
limit
exampl
occur
bacteri
infect
borrelia
burgdorferi
caus
lyme
diseas
antibiot
abrog
antibodi
respons
elisa
result
neg
patient
known
diseas
treat
earli
dattwyl
et
al
earli
case
reactiv
uniqu
antigen
ospa
also
neg
serolog
assay
despit
demonstr
tcell
possibl
scenario
bioterror
attack
distinguish
victim
perpetr
respons
kraus
et
al
analysi
sera
found
antibodi
b
burgdorferi
threshold
detect
convent
assay
detect
bound
form
immun
complex
schutzer
et
al
schutzer
coyl
anthrax
use
exampl
investigatori
lead
gener
consid
scenario
toto
elderli
woman
die
connecticut
inhal
anthrax
clearli
occup
exposur
known
contact
anyon
anthrax
possibl
contact
crosscontamin
mail
howev
case
occur
index
case
context
mail
attack
would
reason
question
travel
histori
work
receiv
use
sporecontamin
product
anthrax
endem
area
similarli
vietnames
woman
die
inhal
anthrax
new
york
citi
would
also
question
investig
would
use
search
direct
indirect
evid
anthrax
physic
examin
contact
close
neighbor
inspect
cultur
workplac
apart
apart
complex
especi
contigu
neighbor
import
detect
presenc
b
anthraci
cowork
friend
neighbor
contact
could
serum
analyz
antibodi
antigen
b
anthraci
sampl
could
frozen
one
posit
would
avail
comparison
studi
futur
minimum
type
studi
could
serv
futur
control
data
geograph
region
molecular
method
even
trace
amount
might
detect
lasken
egholm
although
parallel
investig
background
control
would
necessari
although
hypothet
sever
result
could
occur
consid
separ
first
exampl
close
contact
posit
igm
one
b
anthraci
antigen
pa
find
would
suggest
person
recent
exposur
noth
els
treat
individu
could
conceiv
one
knowingli
unknowingli
pass
spore
patient
given
octob
onset
ill
late
mail
sequenc
would
less
like
individu
perpetr
rather
recent
victim
howev
person
iggposit
sever
possibl
perhap
person
past
exposur
endem
region
treat
eg
haiti
anthrax
known
charcoal
diseas
person
could
vaccin
bona
fide
reason
research
receiv
occup
exposur
person
could
obtain
vaccin
origin
legitim
illeg
purpos
nevertheless
vaccin
vaccin
usag
may
clinic
trial
anim
experiment
anim
vaccin
may
obtain
without
strict
record
keep
person
could
load
mail
rel
impun
protect
antibodi
gener
vaccin
situat
similar
one
requir
intellig
inform
regard
access
abil
motiv
area
recombin
vaccin
develop
use
antibodi
respons
would
differ
someon
use
one
type
recombin
vaccin
compar
someon
use
anoth
type
vaccin
nevertheless
find
igg
one
antigen
b
anthraci
could
point
investig
toward
seroposit
individu
wherea
igm
find
could
justifi
critic
therapi
inform
point
particular
individu
investig
could
extend
search
ingest
inject
antibiot
illustr
ciprofloxacin
exampl
question
would
rais
regard
access
antibiot
recent
ingestioninject
halflif
antibiot
halflif
metabolit
antibiot
bodi
fluid
tissu
residu
found
illustr
use
host
factor
microbi
forens
data
earlier
section
someon
antibiot
system
may
protect
follow
exposur
potenti
pathogen
person
would
antibodyneg
like
antigenand
microbi
dnarnaneg
infect
would
erad
organ
prolifer
signific
quantiti
widespread
prophylact
use
ciprofloxacin
period
follow
anthrax
mail
attack
illustr
understudi
area
ciprofloxacin
increasingli
associ
tendon
ruptur
achil
tendon
akali
niranjan
palin
gough
godoysanto
et
al
futur
better
methodolog
follow
pharmacokinet
antiinfect
compound
may
forens
implic
last
exampl
someon
take
antibiot
prophylact
manipul
lethal
microb
may
exhibit
side
effect
proper
context
investig
may
add
pictur
possibl
culpabl
area
far
establish
point
time
strategi
employ
examin
suspici
possibl
accident
transmiss
infect
approach
illustr
recent
studi
avian
influenza
use
multitud
assay
tool
determin
persontoperson
spread
mode
transmiss
includ
viral
cultur
serolog
analysi
immunohistochem
assay
revers
transcriptase
polymeras
chain
reaction
rtpcr
analysi
genet
sequenc
ungchusak
et
al
meinel
et
al
like
futur
understand
immun
system
evolv
technolog
bring
new
analyt
power
field
interim
make
good
use
proven
principl
forens
purpos
